The Improved Health Utility of Once-Weekly Subcutaneous Semaglutide 2.4 mg Compared With Placebo in the STEP 1-4 Obesity Trials
Diabetes Obes Metab 2023 DOI 10.1111/dom.15090
Patient-reported outcomes and evaluations serve to shape policy through cost-effectiveness comparisons, assessing the incremental expenses of an intervention against the incremental enhancement in quality-adjusted life years.
This study evaluated the impact of weekly subcutaneous semaglutide 2.4 mg treatment versus placebo on the SF-6D version 2 (SF-6Dv2) and EQ-5D-Three-Level (EQ-5D-3L) utility scores throughout the STEP 1-4 trials.
Semaglutide 2.4 mg demonstrated minor improvements in health utility scores from the baseline at week 68 across all trials, whereas placebo scores generally declined. The SF-6Dv2 treatment differences at week 68 between semaglutide 2.4 mg and placebo were significant in STEP 1 and 4, but not in STEP 2 or 3. Meanwhile, EQ-5D-3L treatment differences at week 68 for semaglutide 2.4 mg versus placebo were significant in STEP 1, 2 and 4, but not STEP 3.
Keywords:
